Hephaistos-Pharma, a Lyon, France-based biotechnology company developing immunotherapies against cancer, raised a total of $10.3M in Seed funding.
The round included:
- a €4.5M led by Elaia with participation from xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business Angels, and
- €5.8M non-dilutive funding from the EIC accelerator, Bpifrance i-Nov, and France 2030 clinical grant.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Frederic Caroff, Hephaistos-Pharma is a preclinical biotech company developing immunostimulants against cancer with a technology for intravenous administration, opening the way to metastatic and hard-to-treat indications. ONCO-Boost is a first-in-class immunostimulant targeting innate immune response to treat cancers non-responding to current regimens, including immunotherapies.
The company is also involved in the SyStInn consortium headed by academic partners that received an additional 9.8M€ grant from the French National Research Agency RHU program, which will part-fund clinical trials evaluating ONCO-Boost.
Hephaistos-Pharma also has a subsidiary in Liège, Belgium.
FinSMEs